Lyrica (Pregabalin) Korean Post Marketing Surveillance Study

Viatris

Status: Completed

Conditions: Fibromyalgia; Epilepsy; Neuropathic Pain; Post-market Surveillance

Treatments: Drug: pregabalin (Lyrica)

Study type: Observational

Funder types: Industry

Identifiers

NCT01220180

A0081138

Details and patient eligibility

About

This study collects post-marketing safety and efficacy surveillance data in real world clinical use of pregabalin for its approved indications in Korea.

Full description

continuous patients with target disorders in collaborating institutions

Enrollment: 4,175 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Any patient treated with pregabalin for an approved indication by Korean Food and Drug Administration

Exclusion criteria

• Non-consenting
• Hypersensitivity to the active substance or to any of the excipients
• galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption.

Trial design

4,175 participants in 3 patient groups

Epilepsy

Treatment:

Drug: pregabalin (Lyrica)

Drug: pregabalin (Lyrica)

Drug: pregabalin (Lyrica)

Neuropathic Pain

Treatment:

Drug: pregabalin (Lyrica)

Drug: pregabalin (Lyrica)

Drug: pregabalin (Lyrica)

Fibromyalgia

Treatment:

Drug: pregabalin (Lyrica)

Drug: pregabalin (Lyrica)

Drug: pregabalin (Lyrica)